← Eichor
Condition: Advanced Biliary Tract Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Biliary Tract Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)
Phase 3 · 3 location(s) · Rajiv Gandhi Cancer Institute & Research Center, India · NCT06712420This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
Phase 2/Phase 3 · 5 location(s) · InnoPharmax Inc. · NCT05065957At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 11 location(s) · TiumBio Co., Ltd. · NCT05784688Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Phase 2 · 2 location(s) · Case Comprehensive Cancer Center · NCT07146646Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
Phase 1 · 2 location(s) · University of Maryland, Baltimore · NCT06546969Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Phase 1/Phase 2 · 11 location(s) · Genfit · NCT05874414CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06937567Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
Phase 2 · 1 location(s) · Asan Medical Center · NCT05222971Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 6 location(s) · ModeX Therapeutics, An OPKO Health Company · NCT06239194CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06230471ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT07151118Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07025174Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
Phase N/A · 1 location(s) · CHA University · NCT07142226AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metasta
Phase 1/Phase 2 · 18 location(s) · Avenzo Therapeutics, Inc. · NCT07038343Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Phase 2 · 1 location(s) · Columbia University · NCT07433673A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Phase 1 · 6 location(s) · SEED Therapeutics, Inc. · NCT07197554Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT06893380Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 21 location(s) · I-Mab Biopharma US Limited · NCT04900818A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Phase 1 · 2 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06043466Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Phase 1 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07614061Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unr
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06852287Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Local
Phase 2 · 1 location(s) · Xiujuan Qu · NCT07506057A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/Phase 2 · 67 location(s) · AstraZeneca · NCT05123482Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Phase 2 · 41 location(s) · UNICANCER · NCT06529718GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）
Phase N/A · 1 location(s) · Fudan University · NCT06988592Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing So
Phase 1 · 7 location(s) · Myeloid Therapeutics · NCT07334119Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-posi
Phase 3 · 185 location(s) · Jazz Pharmaceuticals · NCT06282575
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.